Our Technology

Shift Pharmaceuticals is developing a drug to treat all forms of Spinal Muscular Atrophy (SMA) by targeting an important “back-up” gene, SMN2 that is present in all SMA patients. Antisense oligos (ASOs) targeting regulatory elements in SMN2 including Element1 (E1) are particularly effective in shifting SMN2 to produce a functional protein.